With more than 24 years’ experience of legal practices within the life sciences sector, Scott Farnsworth is highly regarded by his clients and peers as a leading practitioner, well known for his understanding of scientific and technical subject matter, together with his structuring of transactions and compensation models. Having worked as external counsel to large pharma for over 7 years, Scott’s practice is extensive, attracting instructions from across the United Kingdom and mainland Europe and has grown entirely through recommendations and referrals. Scott’s clients within the sector include PLCs, charities, pre-clinical and clinical CROs, SMEs, universities and spin-outs from universities, TTOs, and private inventors, specialising in biotechnology, drug discovery, therapeutics and delivery, medical devices, and the conduct and management of clinical trials.
Patents & life sciences
Scott’s most recent instructions include advice and written work for pre-clinical R&D, collaborative DMPK/PBPK modelling programmes (UK, EU, and US), early stage drug development with analyses for clinical candidates and hit to lead compounds, integrated drug discovery programmes, MSAs, MTAs, and compound evaluations, a Named Patient Supply (special medicinal product), a patent licence of repurposed (second medical use) drugs for specified disease states, patent and know-how licences of peptide based haemostat (UK, EU, US, and ‘Greater China’), LX-2 cell line transfers with cross-licence, spin-out licence of compounds and know-how with revenue sharing, study start-ups for clinical trials, clinical trials for phases I and II IND HER-2 negative breast cancer (mCTA) (UK, EU, and US), and equipment transfer and handling for +ve COVID-19 testing.